In 2016, Hecht et al. (NCT00680901: a phase III trial) gauged the therapeutic benefits and safety of frontline lapatinib plus capecitabine plus oxaliplatin (lapatinib group, n = 272) versus placebo plus capecitabine plus oxaliplatin (placebo group, n = 273) in 545 previously untreated patients with advanced or metastatic HER2-positive GC/GEJC [22]. Here, ERBB2 is linked to gastric cancer.